Floatz logo

(+)-VINCRISTINE

Kidney Neoplasms

Merck Sharp & Dohme LLCSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Kidney Neoplasms cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
su011248
Pfizer
Phase 3BB
FENTANYL
RenJi Hospital
Phase 4BB

View all 47 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →